PRESS RELEASE -
January 27th 2009
Cavit Sciences, Inc. ("Cavit") (OTCBB: CVIT) announced today the
following update to its shareholders:
Contact: Maggie
Smyth, Interim CEO
info@cavitsciences.com
www.CavitSciences.com
Shareholders update:
We have been informed that our first Purchase Order will be
delivered earlier than expected, and that our website will be ready
for our January 30th meeting in Virginia with our marketing group and
design crew, with this news we have been able to move the launch date
of our Supplement Line and Website to February 15th.
We have signed a consulting and development agreement with Dr.
Joseph Mix who will be helping with our vision for the optimal product
and the direction of our Supplement Line. We are hopeful Dr. Mix will
be the first of many Doctors and Advisors to our company as we grow.
We have also engaged the services of "Internet Marketing
Communications" to help with the marketing of our product line along
with literature, videos and teleconferencing calls.
We are looking to add 1 or 2 new products, along with our research
and published journals every few months, economy permitting.
We will continually reevaluate our supplements as new and tested
information comes our way.
Unfortunately our company's past management is refusing to turn
over books and ledgers. We will diligently work at rectifying this
situation, but are confident this will not alter the company from
moving forward.
In regards to information we requested from past management about
our products, we have not received any response. We were informed that
the company had 15 supplement formulas ready to go, but so far we have
only located 5 in the files sent to us. This was confirmed by the
manufacturer, but through the work and commitment of present
management and advisors we will formulate future products in the
months ahead.
Our main concern is to become an income producing company, after
that, the BOD will sit down and decide what to do about the return of
Cavit's property and reimbursement of money and shares.
Our long-term plan is to turn our company into a mini Berkshire
Hathaway model with a percentage of every quarters profits going to
investing in brand-name companies we consider to be undervalued, our
own stock buyback or a return to the shareholders. We vow to not
repeat the previous practices of past management.
We have a lot ahead of us, but we feel with the right people we now
have on our team, and a solid business plan, we will be successful.
Cavit Sciences, Inc. ("Cavit") is a biotechnology company engaged
in developing treatments and prevention for cancer, viral infections
and related diseases along with supplements for the growing
population. Additional information regarding our drug development,
supplement line and Company information is available on the Company's
website at: www.cavitsciences.com.
Statements contained herein that are not historical fact may be
orward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934, that are subject to a variety of risks and uncertainties.
There are a number of important factors that could cause actual
results to differ materially from those projected or suggested in any
forward-looking statements made by Cavit. These factors include, but
are not limited to: (i) the ability of Cavit to successfully raise
financing, and (ii) the ability of Cavit to successfully commercialize
its products in certain markets. Additional factors that would cause
actual results to differ materially from those projected or suggested
in any forward-looking statements are contained in Cavit's filings
with the Securities and Exchange Commission, including those factors
discussed under the caption "Risk Factors" for Cavit on Form 10-K
filed on April 18, 2008 and its subsequently filed Forms 10-Q.
 |
Contact: Maggie Smyth Interim CEO (973) 278-7327 Cavit Sciences,
Inc. www.cavitsciences.com
|
|
SOURCE: Cavit Sciences, Inc.
